Henn Matthew R.'s Form 4 filing
Seres Therapeutics, Inc. (MCRB) · filed May 19, 2025
- Accession no.
- 0000950170-25-074323
- Filed
- May 19, 2025
- Trade date
- May 15-16, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $560.56. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henn Matthew R.CIK 0001767321 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | Common Stock | MOption exerciseDisposed | −140 | $0.00 | $0 | 985 | Direct | |
| May 15, 2025 | Common Stock | MOption exerciseDisposed | −98 | $0.00 | $0 | 1,073 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Referenced by the price of 2 transactions in Table I.
Remarks
Chief Scientific Officer and EVP